Preclinical Imaging Market Size, Share, Growth, and Industry Analysis, By Type (CT Imaging, MRI Imaging, PET/SPECT Imaging, Multi-modal Imaging, Optical Imaging, Ultrasound Imaging, Photoacoustic Imaging, Reagents, Services), By Application (Hospital, Diagnostics Center, Others), Regional Insights and Forecast to 2035

PRECLINICAL IMAGING MARKET OVERVIEW

The global Preclinical Imaging Market size estimated at USD 2.81 billion in 2026 and is projected to reach USD 4.43 billion by 2035, growing at a CAGR of 5.2% from 2026 to 2035.

The preclinical imaging market is expanding due to increasing laboratory research activity, rising biologics development, and growing use of molecular imaging technologies in animal-based studies. More than 72% of pharmaceutical companies use advanced imaging platforms during early-stage drug evaluation. PET/SPECT imaging systems accounted for nearly 31% of installed preclinical imaging equipment in 2025, while MRI imaging represented 24% of usage across academic laboratories. Over 18,000 preclinical imaging studies were registered globally during 2024. Optical imaging systems processed above 42% of small-animal imaging procedures because of lower operational complexity. More than 640 research institutions globally adopted multimodal imaging platforms for oncology and neurology investigations during 2025.

The United States accounted for nearly 38% of global preclinical imaging installations in 2025 due to strong pharmaceutical research infrastructure and expanding federal biomedical funding. More than 3,900 active preclinical research laboratories operated across the country during 2024. Around 67% of U.S. pharmaceutical companies integrated molecular imaging technologies into oncology drug discovery workflows. MRI imaging systems represented 28% of total imaging equipment in American preclinical laboratories, while optical imaging accounted for 36% of routine procedures. Over 1,400 animal imaging systems were installed in academic medical centers across the U.S. in 2025. Increased investments in neuroscience and immunology research supported adoption of PET and ultrasound imaging systems nationwide.

KEY FINDINGS OF PRECLINICAL IMAGING MARKET

LATEST TRENDS

The preclinical imaging market is witnessing strong technological advancement due to increasing focus on precision medicine, molecular diagnostics, and targeted drug development. More than 63% of newly established research laboratories integrated multimodal imaging systems during 2025. PET/MRI hybrid systems experienced 26% installation growth across oncology-focused laboratories. Around 57% of pharmaceutical firms adopted imaging biomarkers to reduce animal testing duration and improve research efficiency. Optical imaging systems remained highly preferred because they contributed nearly 41% of routine preclinical imaging procedures globally.

Artificial intelligence integration has become a major trend in image analysis and automated lesion detection. Nearly 46% of imaging software upgrades introduced AI-assisted quantification capabilities during 2024. Cloud-based data storage platforms supported approximately 38% of collaborative research studies among academic institutions. More than 520 neuroscience research centers implemented high-resolution MRI imaging systems for brain mapping and neurodegenerative disease studies.

MARKET DYNAMICS

Driver

Rising demand for pharmaceuticals and biologics.

The increasing number of drug discovery programs globally continues to drive demand for preclinical imaging technologies. More than 21,000 active pharmaceutical compounds were under preclinical investigation during 2025, with oncology accounting for 34% of total studies. Approximately 69% of biologics developers incorporated imaging-based validation methods into toxicology and efficacy testing workflows. PET imaging systems improved molecular tracking precision by nearly 44% compared to traditional histology-based assessments.

Restraint

High installation and operational costs.

High acquisition and maintenance expenses continue to limit adoption of advanced preclinical imaging systems in smaller laboratories. MRI imaging systems require infrastructure investments exceeding standard laboratory equipment budgets by nearly 47%. Around 43% of research institutions reported delays in equipment upgrades because of operational cost pressures. Imaging reagents and radioactive tracers accounted for 26% of annual laboratory operational expenditure in nuclear imaging studies. More than 38% of small biotechnology firms relied on third-party imaging facilities instead of direct equipment ownership.

Opportunity

Growth in personalized medicines.

The expansion of personalized medicine programs is creating substantial opportunities for preclinical imaging technologies. More than 61% of targeted therapy developers adopted molecular imaging tools for biomarker assessment during 2025. Precision oncology studies represented nearly 37% of preclinical imaging demand globally. High-resolution imaging systems improved tumor localization accuracy by approximately 42% in experimental drug trials. Around 49% of immunotherapy research projects integrated optical and PET imaging techniques for immune response monitoring. Neurology-focused personalized medicine studies increased by 28% between 2023 and 2025.

Challenge

Complexity in multimodal data integration.

Managing large imaging datasets and integrating outputs from multiple imaging systems remain significant challenges within the preclinical imaging market. Nearly 45% of laboratories reported difficulties in standardizing imaging data across MRI, PET, CT, and optical platforms. Around 39% of research teams experienced delays associated with software interoperability limitations. Data storage requirements for high-resolution imaging studies increased by 52% between 2023 and 2025. Approximately 28% of imaging professionals identified shortages of trained image analysis specialists as a major operational issue.

PRECLINICAL IMAGING MARKET SEGMENTATION

By Type

• CT Imaging: CT imaging represented nearly 16% of the preclinical imaging market during 2025 due to increasing use in bone analysis, pulmonary imaging, and anatomical visualization studies. More than 2,300 small-animal CT systems operated globally across academic and pharmaceutical laboratories. High-resolution CT scanners improved skeletal imaging precision by approximately 38% compared to conventional radiography methods. Around 52% of orthopedic preclinical studies incorporated CT imaging technologies for structural assessment.

• MRI Imaging: MRI imaging accounted for approximately 18% share of the global preclinical imaging market due to superior soft tissue contrast and high-resolution neurological imaging capabilities. More than 1,700 dedicated preclinical MRI systems operated worldwide during 2025. Brain imaging applications represented 46% of MRI-based studies globally. Around 61% of neuroscience research centers adopted MRI technologies for neurodegenerative disease modeling and functional brain mapping. High-field MRI systems improved tissue differentiation accuracy by nearly 43%.

• PET/SPECT Imaging: PET/SPECT imaging maintained nearly 21% market share in 2025 because of increasing molecular imaging applications in oncology, cardiology, and immunology research. Around 68% of oncology-focused preclinical studies utilized PET imaging biomarkers during drug development. More than 1,500 PET/SPECT systems were active globally in pharmaceutical and academic laboratories. Nuclear imaging tracers improved disease detection sensitivity by approximately 49% compared to standard optical methods. North America represented 43% of total PET/SPECT imaging installations worldwide.

• Multi-modal Imaging: Multi-modal imaging systems represented approximately 14% of the preclinical imaging market because of growing demand for integrated anatomical and functional imaging analysis. More than 640 research institutions implemented hybrid imaging platforms combining MRI, PET, CT, and optical technologies during 2025. Integrated systems improved imaging workflow efficiency by nearly 37%. Around 48% of pharmaceutical companies preferred multimodal platforms for comprehensive oncology drug validation.

• Optical Imaging: Optical imaging held nearly 29% share of the global preclinical imaging market, making it the leading segment by procedural volume during 2025. Around 42% of small-animal imaging procedures globally used fluorescence or bioluminescence imaging systems. Optical imaging platforms improved molecular visualization sensitivity by approximately 36% in oncology studies. More than 3,200 optical imaging systems were installed across research laboratories worldwide. Asia-Pacific accounted for nearly 26% of optical imaging demand because of increasing biomedical research activities.

• Ultrasound Imaging: Ultrasound imaging represented approximately 9% of the preclinical imaging market due to increasing cardiovascular and developmental biology research applications. More than 1,100 preclinical ultrasound systems operated globally during 2025. Cardiovascular imaging studies contributed nearly 39% of ultrasound imaging demand. High-frequency ultrasound improved vascular imaging resolution by approximately 31% in animal models. Compact ultrasound systems accounted for 22% of new imaging installations because of portability advantages.

• Photoacoustic Imaging: Photoacoustic imaging accounted for approximately 5% share of the preclinical imaging market due to increasing demand for functional and vascular imaging applications. More than 420 photoacoustic imaging systems were operational globally during 2025. Tumor oxygenation analysis represented nearly 33% of photoacoustic imaging studies. Hybrid optical-photoacoustic platforms improved tissue contrast sensitivity by approximately 29% compared to standalone optical systems. Asia-Pacific contributed around 24% of total installations due to rising biomedical innovation programs.

• Reagents: Reagents represented nearly 11% of the preclinical imaging market because imaging tracers, fluorescent dyes, and contrast agents remain essential for molecular visualization. Around 62% of PET imaging procedures required isotope-based reagents during 2025. More than 2,600 imaging laboratories globally utilized specialized MRI and optical contrast agents for experimental studies. Oncology applications contributed approximately 44% of imaging reagent consumption worldwide. Fluorescent imaging probes improved biomarker detection precision by nearly 34% compared to standard staining procedures.

• Services: Services accounted for approximately 11% share of the global preclinical imaging market because many biotechnology firms outsource imaging procedures and analytical support. More than 41% of small pharmaceutical companies relied on external imaging service providers during 2025. Imaging analysis services improved workflow efficiency by approximately 32% in outsourced drug development studies. Contract research organizations represented nearly 46% of total imaging service demand globally. Asia-Pacific recorded 21% growth in imaging outsourcing activities between 2023 and 2025.

By Application

• Hospital: Hospitals represented nearly 46% of the preclinical imaging market application share during 2025 because of extensive translational research infrastructure and integrated biomedical laboratories. More than 2,900 teaching hospitals globally operated dedicated preclinical imaging facilities. Oncology and neurology studies accounted for approximately 58% of hospital-based imaging activities. MRI imaging systems represented 27% of hospital imaging installations worldwide. Around 64% of academic hospitals integrated multimodal imaging technologies into drug discovery workflows.

• Diagnostics Center: Diagnostic centers accounted for approximately 34% of the preclinical imaging market because of increasing demand for specialized imaging services and biomarker validation studies. More than 1,800 dedicated diagnostic imaging laboratories globally provided preclinical imaging support during 2025. PET/SPECT imaging represented nearly 31% of diagnostic center imaging procedures. Around 48% of pharmaceutical outsourcing contracts involved independent imaging diagnostic centers. Europe contributed approximately 29% of global diagnostic center demand due to strong clinical research infrastructure.

• Others: The others segment represented nearly 20% of the preclinical imaging market and included contract research organizations, biotechnology companies, and government research institutes. More than 1,400 biotechnology firms utilized imaging platforms for drug screening and molecular analysis during 2025. Contract research organizations contributed approximately 44% of imaging activities within this segment. Around 36% of government-funded research projects integrated optical imaging technologies for infectious disease studies.

PRECLINICAL IMAGING MARKET REGIONAL OUTLOOK

• North America

North America dominated the preclinical imaging market with nearly 39% global share during 2025. The United States represented approximately 82% of regional imaging demand because of strong pharmaceutical and biotechnology research activities. More than 3,900 active preclinical laboratories operated across North America during 2024.

PET/SPECT imaging systems accounted for nearly 28% of total installations in the region. Around 66% of oncology drug development studies utilized molecular imaging technologies for biomarker validation. Academic medical centers contributed approximately 41% of regional imaging activities. More than 1,500 multimodal imaging systems were operational across North American research institutions during 2025.

• Europe

Europe accounted for approximately 28% of the global preclinical imaging market during 2025 due to extensive biomedical research funding and strong pharmaceutical manufacturing infrastructure. Germany, the United Kingdom, and France collectively represented nearly 61% of European imaging demand. More than 2,200 preclinical imaging laboratories operated across Europe during 2024.

MRI imaging systems contributed approximately 26% of regional imaging installations. Around 54% of neuroscience studies conducted in Europe integrated high-field MRI technologies for disease modeling and translational analysis. PET/SPECT imaging adoption increased by 21% between 2023 and 2025 due to expansion of oncology biomarker research.

• Asia-Pacific

Asia-Pacific represented nearly 24% of the global preclinical imaging market during 2025 because of rapidly growing pharmaceutical manufacturing and expanding biotechnology research sectors. China, Japan, and South Korea contributed approximately 68% of regional imaging demand. More than 2,700 biomedical research laboratories operated across Asia-Pacific during 2024.

Optical imaging systems represented nearly 38% of total installations because of affordability and operational flexibility. Around 52% of regional biotechnology startups integrated imaging-based drug validation workflows during 2025. Photoacoustic imaging adoption increased by 23% across Asia-Pacific due to expanding vascular disease and cancer research programs.

• Middle East & Africa

Middle East & Africa accounted for approximately 9% of the global preclinical imaging market during 2025 due to expanding biomedical research infrastructure and increasing healthcare innovation investments. The United Arab Emirates, Saudi Arabia, and South Africa represented nearly 63% of regional imaging demand. More than 640 biomedical research laboratories operated across the region during 2024.

Optical imaging systems accounted for approximately 35% of installed imaging platforms because of lower operational costs and simplified laboratory integration. PET/SPECT imaging adoption increased by 17% between 2023 and 2025 due to expanding oncology and metabolic disease research initiatives. Academic institutions contributed approximately 43% of imaging utilization across Middle East & Africa.

LIST OF TOP PRECLINICAL IMAGING COMPANIES

• Bruker Corporation
• Siemens A.G.
• General Electric (GE)
• TriFoil Imaging
• PerkinElmer, Inc.
• VisualSonics Inc. (Fujifilm)
• Mediso Ltd.
• Agilent Technologies
• MILabs B.V.
• MR Solutions
• Molecubes

List Of Top 2 Companies Market Share

• Bruker Corporation held approximately 19% market share during 2025 due to strong MRI and multimodal imaging portfolio expansion, with more than 2,100 imaging systems installed globally across pharmaceutical and academic research institutions.
• Siemens A.G. accounted for nearly 16% market share in 2025 supported by advanced PET/CT and molecular imaging technologies, with around 1,600 active imaging installations across oncology and translational research laboratories worldwide.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The preclinical imaging market continues attracting substantial investments due to expansion of precision medicine, oncology research, and molecular diagnostics. More than 62% of pharmaceutical research organizations increased imaging infrastructure spending during 2025. Approximately 540 laboratory modernization projects involving advanced imaging technologies were initiated globally between 2023 and 2025. North America accounted for nearly 41% of total imaging-related investment activity due to strong biotechnology innovation ecosystems. Around 48% of newly funded biomedical research programs incorporated multimodal imaging platforms for translational drug development.

Asia-Pacific experienced 29% growth in imaging-focused laboratory expansion projects during 2024. More than 370 biotechnology startups received institutional support for imaging-guided biomarker research. AI-assisted image analysis attracted approximately 33% of software-focused imaging investments globally. Universities and pharmaceutical companies established over 260 collaborative imaging research agreements between 2023 and 2025. Demand for compact imaging systems also increased by 24% because of rising adoption among mid-sized research laboratories.

NEW PRODUCT DEVELOPMENT

New product development in the preclinical imaging market is focused on AI integration, hybrid imaging platforms, miniaturization, and high-resolution molecular imaging systems. More than 49% of newly launched imaging products during 2025 included AI-based automated analysis capabilities. Hybrid PET/MRI systems improved imaging precision by approximately 38% in oncology and neurological disease models. Around 31% of newly introduced platforms supported cloud-enabled collaborative image processing functions.

Compact imaging systems represented nearly 22% of new product launches because of increasing demand from small and medium-sized research facilities. More than 280 next-generation optical imaging systems entered the market between 2023 and 2025. Ultrasound imaging manufacturers improved vascular imaging sensitivity by approximately 27% through high-frequency transducer development. Around 44% of imaging software innovations focused on automated lesion quantification and biomarker visualization. Photoacoustic imaging products also experienced significant innovation, with system deployment increasing by 23% globally.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, Bruker Corporation expanded its high-field MRI imaging portfolio with enhanced AI-assisted reconstruction technology, improving image processing speed by approximately 34% in neuroscience applications.
• In 2024, PerkinElmer, Inc. launched an upgraded optical imaging platform supporting 29% higher fluorescence sensitivity for oncology and immunology preclinical research studies.
• In 2023, Mediso Ltd. introduced a multimodal PET/CT imaging system with integrated automated calibration, reducing operational workflow time by nearly 21% in laboratory environments.
• In 2025, VisualSonics Inc. (Fujifilm) developed a compact ultrasound imaging system with 31% improved vascular resolution for cardiovascular and developmental biology studies.
• In 2024, MILabs B.V. expanded molecular imaging software integration capabilities, enabling approximately 26% faster multimodal data processing across PET and SPECT imaging workflows.

PRECLINICAL IMAGING MARKET REPORT COVERAGE

The preclinical imaging market report provides extensive coverage of imaging technologies, applications, competitive landscape, regional performance, and innovation trends across pharmaceutical and biotechnology sectors. The report evaluates more than 9 major imaging categories, including MRI, PET/SPECT, CT, optical imaging, ultrasound imaging, photoacoustic imaging, reagents, and imaging services. Around 43% of market analysis focuses on oncology-related imaging applications because cancer drug development remains the largest research area globally.

The report includes detailed assessment of over 25 countries and more than 70 imaging equipment manufacturers operating within the market ecosystem. North America accounted for approximately 39% of analyzed market activity, while Asia-Pacific represented nearly 24% of laboratory expansion projects. More than 520 product launches and technology upgrades introduced between 2023 and 2025 were evaluated for innovation benchmarking. The report also analyzes approximately 640 multimodal imaging installations worldwide and examines adoption trends related to AI-assisted image analysis, cloud-based imaging platforms, and precision medicine workflows.